Disclosure of Conflicts of Interest Postgraduate Institute for Medicine PIM requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest COI they may have as related to the content of this activity.
The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity. Americans with Disabilities Act Event staff will be glad to assist you with any special needs i. Please contact Angela Masand prior to the live event at Fee Information There is no fee associated with this symposium. Attendees will received complimentary breakfast and lunch. Please download meeting materials on your desktop or tablet devices.
Mobile devices, such as iPhones and Androids, do not support these downloads. To sample our content, watch the featured videos below. Join Today! To contact GME, email us at [email protected]. Skip to main content. Pinterest Facebook. Create new account Request new password. User menu Contact Us. GME Meeting Planner. Program Overview The GME Psychiatry Update series of 15 meetings will highlight the latest advances in diagnostic and therapeutic issues in patients with bipolar disorder, major depression, sleep disturbances, and schizophrenia.
Target Audience This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, and registered nurses who care for patients with psychiatric illnesses.
Educational Objectives Upon completion of the activity, participants should be better able to: - Identify the red flags for bipolar disorder including the mixed specifier and DSM-5 changes in diagnosis. Davangere P. Devanand, MD. Karl Doghramji, MD. Oliver Freudenreich, MD. Sanjay Gupta, MD. David Henderson, MD. Robert M. However, survey data show that health care providers may lack confidence in the management of patients who have an inadequate response to an antidepressant.
The major barriers to achieving full recovery are the continuation of residual symptoms and treatment-emergent symptoms associated with antidepressants. Even in those responding to antidepressants, residual and treatment-emergent symptoms such as weight gain, sleep disturbance, and sexual dysfunction can impede adherence and recovery.
Additionally, poor cognitive functioning is an obstacle to remission. Although tools are available for the evaluation and monitoring of cognitive function in patients with MDD, they remain underutilized. In this enduring activity, expert faculty will provide opportunities to enhance knowledge and competence in the ability to differentiate residual and treatment-emergent symptoms and better assess and manage symptoms using evidence-based strategies to optimize available therapies.
At any given time, roughly one-quarter of individuals taking antipsychotics experience TD, a condition characterized by involuntary movements of the face and body.
Moreover, as the use of antipsychotics has expanded to disorders such as depression, behavioral disorders, and dementia, TD is no longer primarily limited to patients with schizophrenia. Recently, the US FDA approved 2 medications, both vesicular monoamine transporter 2 VMAT2 inhibitors, to treat TD, giving patients access to the first well-tolerated oral treatments shown to be effective for this condition.
To ensure that patients receive maximum benefit from this advance in TD treatment, clinicians must learn how to integrate VMAT2 inhibitors into their practice. In this activity, an expert faculty member will dispel common myths about TD, educating clinicians about how to recognize and diagnose TD promptly, how VMAT2 inhibitors work to improve TD symptoms, how the 2 approved agents differ, and how VMAT2 inhibitors can be used alongside other strategies to improve outcomes for patients with TD.
Major depressive disorder MDD is a highly heterogeneous disorder that is increasingly seen as a continuum, with emphasis on overlapping and subthreshold symptoms. To address this issue, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders DSM-5 included the use of specifiers, such as mixed features and anxious distress, with the diagnosis of MDD. Although DSM-5 specifiers improve utility and precision in the diagnosis of MDD and related disorders, they may not be widely adopted because some clinicians maintain a categorical approach toward depression.
The risk when clinicians avoid specifiers is significant because patients with diverse depressive illnesses should be diagnosed, monitored, and treated differently.
Further, compared with MDD alone, the presence of mixed features or anxious distress in patients with MDD may be associated with diminished response to antidepressants, more severe symptoms, increased hospitalization, greater risk for suicide, and other deleterious outcomes.
It is important for health care providers to appreciate the importance of MDD specifiers, their diagnostic criteria, and implications for evidence-based treatment.
This activity was created to enhance knowledge and competence of health care providers who evaluate and manage patients with depression and clinical features of hypomania, mania, or anxiety. Schizophrenia, by nature, presents manifold challenges to the HCP directing neuropsychiatric care.
Not only do practical matters like medication adherence play a role in the success of therapy, but it behooves clinicians to also have a well-informed understanding of the symptomatology and treatment course of the disease.
Atypical antipsychotics are the mainstay of initial pharmacotherapy, with oral agents being preferred first. However, they have sometimes been associated with poor patient adherence, which is associated with suboptimal clinical outcomes.
In contrast, improving adherence may enhance quality of life and reduce the risk of hospitalization, thereby potentially lowering health resource utilization and its associated costs. Healthcare professionals who are: psychiatrists and primary care physicians; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in psychiatry; and those who otherwise commonly care for or clinically encounter patients who have schizophrenia.
Opioid use disorder OUD affects millions of individuals globally and is best defined by the Diagnostic and Statistic Manual of Mental Disorders, Fifth Edition DSM-5 as a condition due to tolerance, manifestation of physical dependence, and loss of control leading to health hazards.
Jump to navigation. Course Director: Melanie T. Gentry, M. Sawchuk, Ph. Our flagship course, Psychiatry Clinical Updates formerly known as Psychiatry Clinical Reviews , is aimed at providing clinically relevant updates for the management of psychiatric problems across the lifespan. Topics to be covered include updates and clinical pearls on depression, bipolar disorder, schizophrenia, suicide, addiction, and cognitive disorders, as well as evidence-based psychotherapy and emerging novel pharmacotherapies.
This multidisciplinary course is intended for healthcare providers who see patients with psychiatric indications. Disciplines include psychiatrists, family medicine and primary care providers, neurologists and as well as allied health personnel including nurse practitioners, physician assistants and nurses.
Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure s which may be discussed or taught in this course.
Click here to view the program schedule on your mobile device. Attendees are asked to comply with all live course and conference guidelines.
Guest rooms have been reserved for attendees and their guests with special course rates at the Hyatt Regency Maui Resort and Spa.
0コメント